GMAB, is a biotechnology company known for its innovative antibody therapeutics. Established in 1999 and based in Copenhagen, ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

Genmab A/S (NASDAQ:GMAB – Free Report) had its price target decreased by Truist Financial from $50.00 to $45.00 in a report ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...

William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...

William Blair upgraded Genmab (GMAB) to Outperform from Market Perform.Optimize Your Investment Research with SparkEffectively assess a stock's ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

COPENHAGEN, Denmark; March 4, 2025 - Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses ...

COPENHAGEN, Denmark - Genmab (CSE:GMAB) A/S (NASDAQ:GMAB), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $14.7 billion and an excellent financial ...

Ben Stansall - WPA Pool/Getty Images Prince William and Catherine kicked off their visit to South Wales at Pontypridd Market. The heir to the throne and his wife donned aprons as they tried their ...

When Prince William and Kate became Prince and Princess of Wales following the death of Queen Elizabeth, they quickly made it clear that a connection with the Welsh people was a priority.